Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Mucodyne Paediatric Liquid to be discontinued

The manufacturer of carbocisteine 125mg/5ml oral solution (Mucodyne® Paediatric) has written to healthcare professionals advising that this product has been discontinued due to manufacturing difficulties and will no longer be available from April 2015.

The 250mg/5ml solution remains available and may be an appropriate alternative if the required dose can be measured and delivered. An oral medicines syringe may be required. It should be noted however that the Summary of Product Characteristics advises that the product is not suitable for children and that the paediatric product should be used!

The normal daily dosage is 20 mg/kg bodyweight in divided doses. The previously recommended doses for the 125mg/5ml paediatric oral solution were:

  • Children 5 - 12 years: 10 ml three times daily
  • Children 2 - 5 years: 2.5 - 5 ml four times daily

Action: Clinicians should be aware of this product being discontinued. It may be prudent to run clinical system searches to identify any patients who are currently prescribed this product to allow a review and an alternative to be arranged.

Share 'Mucodyne Paediatric Liquid to be discontinued' on Email Share 'Mucodyne Paediatric Liquid to be discontinued' on Delicious Share 'Mucodyne Paediatric Liquid to be discontinued' on Digg Share 'Mucodyne Paediatric Liquid to be discontinued' on Facebook Share 'Mucodyne Paediatric Liquid to be discontinued' on Google+ Share 'Mucodyne Paediatric Liquid to be discontinued' on reddit Share 'Mucodyne Paediatric Liquid to be discontinued' on StumbleUpon Share 'Mucodyne Paediatric Liquid to be discontinued' on Twitter

atomic-wealth

2 Comments to “Mucodyne Paediatric Liquid to be discontinued”

  1. […] carbocisteine liquid that is double the strength of the same presentation discontinued in January 2015. Clinicians should ensure an appropriate dose volume is prescribed when using this […]

    Pingback by Drug Safety Update - April 2017 - Prescribing Advice For GPs — April 25, 2017 #
    Reply

  2. […] there is a summary of letters sent to healthcare professionals since November 2014, including the discontinuation of carbocisteine 125mg/5ml oral […]

    Pingback by Drug Safety Update - February 2015 | Prescribing Advice For GPs — February 17, 2015 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,278 spam comments.

atomic-wealth
fond-illness
summer